Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veracyte reports record Q4 revenue and strategic growth initiatives

Veracyte's Q4 performance reflects strong financials and product advancements, positioning the company for continued growth.
While facing challenges in cost management and operational transitions, Veracyte remains proactive in addressing market demands.
Opportunities for revenue growth and market expansion through new product developments and reimbursement progress are key focus areas.
Overall, Veracyte's strategic initiatives and market positioning suggest a promising outlook for future success.

Veracyte reports robust Q1 earnings, eyes global expansion opportunities

Veracyte's strong Q1 performance was driven by Afirma and Decipher tests, despite challenges in the biopharma business.
The company's focus on global expansion, product enhancement, and evidence generation positions it well for future growth.
Challenges in margins and customer spending require strategic adjustments, but Veracyte remains optimistic about its investment levels.
ESG efforts and commitment to patient outcomes underscore Veracyte's dedication to transforming healthcare and stakeholder value.

Veracyte reports strong Q2 earnings, raises 2023 revenue outlook

Veracyte's Q2 performance reflects robust revenue growth, operational efficiency, and increased market confidence.
While facing challenges in the biopharma segment and manufacturing transitions, the company is well-positioned to capitalize on market opportunities.
With raised revenue projections, strong product performance, and strategic focus areas, Veracyte is poised for continued growth and market expansion.

Veracyte (VCYT) reports robust Q3 performance and eyes market expansion

Veracyte (VCYT) delivered strong financial results in Q3 2023, driven by core testing business growth and strategic partnerships.
Despite supply chain challenges, the company remains focused on market expansion, operational optimization, and cash flow generation.
With a positive outlook for 2024 and a focus on evidence generation and market penetration, Veracyte is poised for continued growth and transformation in cancer care.

Veracyte reports record 2023 revenue, eyes market expansion in 2024

Veracyte's strong 2023 performance sets the stage for continued growth in 2024.
Balancing short-term challenges with long-term opportunities for market expansion.
Strategic acquisitions and product developments position Veracyte well in evolving markets.
Maintaining financial guidance and operational focus key to sustained success.

Veracyte's Q1 2024 earnings call showcased strong revenue growth driven by Decipher Prostate and Afirma.
The company raised total revenue guidance for 2024 and highlighted interest from biopharma in data projects.
While facing challenges like FDA LDT regulation, Veracyte remains focused on existing growth drivers and global expansion.
Excitement surrounds the company's growth trajectory and opportunities in Decipher, MRD testing, and new cancer challenges.

Veracyte reports stellar Q2 results, eyes revenue growth opportunities

Veracyte's Q2 2024 performance reflects robust revenue growth, driven by strong testing revenue and strategic initiatives focused on market expansion and innovation.
Despite facing seasonal revenue fluctuations, the company remains optimistic about achieving its raised revenue guidance for 2024, underpinned by the growth in testing business.
The emphasis on profitability, cash generation, and revenue growth through Decipher and Afirma positions Veracyte well for sustained financial success and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C. Findings from two posters suggest that the Envisia Genomic Classifier helps improve diagnosis and.

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte's Genomic Tests in Interstitial Lung Disease and Lung Cancer

Growing demand for Veracyte's diagnostic tests helped its top line surge in Q1. The company could turn a profit as early as the second half of this decade.

Here's Why This Little-Known Growth Stock Is a Buy

With its range of products, Veracyte displays a robust and diverse portfolio, targeting multiple areas in oncology. Veracyte's recent data underscores the company's innovative edge in the field of genomic diagnostics, specifically with the Decipher Prostate Genomic Classifier.

Veracyte: Investing In The Future Of Genomic Diagnostics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing – specifically, the Prosigna te.

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte, Inc. (NASDAQ:VCYT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Mason Carrico - Stephens, Inc. Matt Sykes - Goldman Sachs Andrew Brackmann - William Blair Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2023 Financial Results Webcast.

Veracyte, Inc. (VCYT) Q1 2023 Earnings Call Transcript

Veracyte (VCYT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.20 per share a year ago.

Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2023. “We had an excellent first quarter, as many areas of our business greatly exceeded our expectations. Not only did we deliver strong Afirma and Decipher growth, we also demonstrated continued financial discipline and outstanding execution, which resulted in a meaningfully higher cash balance than we had projected,” said Marc Stapley, Veracyte's.

Veracyte Announces First Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report. The 2023 ESG Report sets the foundation for Veracyte's ESG performance and outlines the company's ambitions to build upon its progress in the years ahead. “As our company has grown, we have embraced our responsibility to advance our ESG efforts,” said Marc Stapley, Veracyte's chief executive officer. “Our inaugural ESG repo.

Veracyte Announces Release of Inaugural ESG Report

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Published Data Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier To Help Guide Therapy in Intermediate-Risk Prostate Cancer.

Data Published in "The Red Journal” Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company's genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24 in Washington, D.C. “We look forward to these new data being shared at ATS 2023, which explore the impact of our Envisia Gen.

Three Abstracts Focusing on the Clinical Utility of Veracyte's Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier.

Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online June 2-6. Three of the accepted abstracts leverage Veracyte's Decipher GRID (Genomic Resource for Intelligent Discovery) database to explore potential opportunities for further personalizing treat.

Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting

The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High?

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know

NEW YORK--(BUSINESS WIRE)--Acuamark Diagnostics has appointed Giulia Kennedy, Ph.D., formerly global chief scientific officer and chief medical officer of diagnostics company Veracyte, to its board of directors. Dr. Kennedy is a prolific research, product and clinical development executive with more than 20 years of experience propelling novel diagnostic technologies from early-phase research to commercialization and adoption. She most recently served as global chief scientific officer and chie.

Acuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease (difficult-to-detect tumor cells that extend beyond the prostate) and who may therefore benefit from systemic treatment intensification. The data show that, in men with high-risk and very high-risk disease, Decipher Prostate scores are highly correlated with upstaging predictions made by a clinical algorithm shown to predict prostate-specific membrane antigen (PSMA) positron emission tomography (PET) positivity.

New Data Reinforce Ability of Veracyte's Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company's Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago.

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company's Multi-Omics Capabilities and Tools for Biopharma Partners

Agios Pharmaceuticals

Verona Pharma

Adicet Bio, Inc.

Janux Therapeutics

OmniAb Inc

Sol-Gel Technologies

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment.

7 Biotech Stocks That Could Be the Next Big Thing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) outlined the company's cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022, the company had $178.9 million in cash, cash equivalents and short-term investments. The majority of these assets are not restricted by the Federal Deposit Insurance Corporation's (FDIC) action to take control of SVB.

Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank

Veracyte's revenue grew at a healthy clip in the fourth quarter. The genomic test company's financial health looks solid.

Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?

Start Time: 16:30 January 1, 0000 5:29 PM ET Veracyte, Inc. (NASDAQ:VCYT ) Q4 2022 Earnings Conference Call February 22, 2023, 16:30 PM ET Company Participants Marc Stapley - CEO Rebecca Chambers - EVP and CFO Tina Nova - President, U.S. CLIA Business Shayla Gorman - Director, IR Conference Call Participants Andrew Brackman - William Blair Dave Delahunt - Goldman Sachs Puneet Souda - SVB Securities Mason Carrico - Stephens, Inc Mike Matson - Needham & Company Yuko Oku - Morgan Stanley Andrew Cooper - Raymond James Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2022 Financial Results Webcast.

Veracyte, Inc. (VCYT) Q4 2022 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2022. “We had an outstanding fourth quarter, driving record revenue and operating cash flows, achieving the best quarter ever for both our Decipher prostate and Afirma thyroid tests,” said Marc Stapley, Veracyte's chief executive officer.

Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) demonstrate that the company's Decipher Prostate Genomic Classifier can improve risk stratification among men with clinically high-risk prostate cancer. The data, from a pre-specified analysis of three phase 3 trials, represent the first validation of any gene-expression biomarker on pre-treatment biopsy samples from prospective randomized trials, and suggest the Decipher test provides clinically useful prognostic information to help personalize shared treatment decision-making.

Data Published in “The Red Journal” Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

News for Veracyte Stock (VCYT)